Indian (NIFTY) Pharma Industry Analysis

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 05 Aug 2026	₹24.2t	₹4.6t	₹647.9b	30.1x	37.4x	5.3x
Fri, 03 Jul 2026	₹23.4t	₹4.5t	₹643.1b	30.2x	36.4x	5.2x
Sun, 31 May 2026	₹22.1t	₹4.5t	₹640.2b	29x	34.5x	4.9x
Tue, 28 Apr 2026	₹21.0t	₹4.3t	₹621.0b	29.3x	33.8x	4.8x
Thu, 26 Mar 2026	₹20.3t	₹4.3t	₹621.2b	25.8x	32.6x	4.7x
Sat, 21 Feb 2026	₹20.0t	₹4.3t	₹620.8b	26.5x	32.3x	4.6x
Mon, 19 Jan 2026	₹20.0t	₹4.2t	₹613.3b	28.1x	32.5x	4.7x
Wed, 17 Dec 2025	₹20.4t	₹4.2t	₹614.4b	28.7x	33.2x	4.8x
Fri, 14 Nov 2025	₹20.4t	₹4.2t	₹609.4b	28.9x	33.5x	4.9x
Sun, 12 Oct 2025	₹20.3t	₹4.1t	₹588.2b	30.2x	34.5x	5x
Tue, 09 Sep 2025	₹20.3t	₹4.1t	₹589.3b	30.3x	34.4x	5x
Thu, 07 Aug 2025	₹19.9t	₹4.0t	₹592.4b	31.3x	33.5x	4.9x
Sat, 05 Jul 2025	₹20.6t	₹4.0t	₹595.4b	33.8x	34.6x	5.2x
Mon, 02 Jun 2025	₹19.9t	₹4.0t	₹594.4b	32x	33.5x	5x
Wed, 30 Apr 2025	₹19.7t	₹3.9t	₹560.8b	29.8x	35.1x	5.1x
Fri, 28 Mar 2025	₹19.4t	₹3.9t	₹559.4b	29.6x	34.8x	5x
Sun, 23 Feb 2025	₹18.6t	₹3.9t	₹561.5b	27.9x	33.1x	4.8x
Tue, 21 Jan 2025	₹20.3t	₹3.8t	₹527.4b	33.4x	38.5x	5.3x
Thu, 19 Dec 2024	₹20.7t	₹3.8t	₹526.7b	34.1x	39.3x	5.4x
Sat, 16 Nov 2024	₹20.2t	₹3.8t	₹520.0b	35.6x	38.8x	5.3x
Mon, 14 Oct 2024	₹21.7t	₹3.7t	₹492.6b	42.6x	44x	5.8x
Wed, 11 Sep 2024	₹21.5t	₹3.7t	₹492.6b	43.4x	43.6x	5.8x
Fri, 09 Aug 2024	₹20.3t	₹3.7t	₹475.8b	38x	42.6x	5.4x
Sun, 07 Jul 2024	₹18.2t	₹3.6t	₹448.3b	34.6x	40.6x	5.1x
Tue, 04 Jun 2024	₹16.8t	₹3.6t	₹452.1b	32.3x	37.2x	4.7x
Thu, 02 May 2024	₹17.0t	₹3.5t	₹418.4b	34.9x	40.6x	4.9x
Sat, 30 Mar 2024	₹17.0t	₹3.5t	₹418.9b	32.1x	40.6x	4.9x
Mon, 26 Feb 2024	₹17.1t	₹3.5t	₹418.6b	34.8x	40.8x	4.9x
Wed, 24 Jan 2024	₹15.8t	₹3.4t	₹397.9b	34.1x	39.7x	4.7x
Fri, 22 Dec 2023	₹14.4t	₹3.4t	₹395.2b	32.5x	36.5x	4.3x
Sun, 19 Nov 2023	₹13.9t	₹3.4t	₹395.0b	31.4x	35.3x	4.1x
Tue, 17 Oct 2023	₹13.2t	₹3.3t	₹369.9b	30x	35.6x	4x
Thu, 14 Sep 2023	₹13.3t	₹3.3t	₹369.5b	30.1x	35.9x	4.1x
Sat, 12 Aug 2023	₹13.1t	₹3.2t	₹361.0b	29.5x	36.2x	4x

Current Industry PE

Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 36.6x.

The industry is trading close to its 3-year average PS ratio of 4.9x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 22% per year over the last three years.
Revenues for these companies have grown 12% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?


IN Market	2.19%
Healthcare	1.50%
Pharma	1.03%
Pharma	1.03%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
500420 Torrent Pharmaceuticals	₹5.00k	2.5% +₹45.9b	41.8%	PE87.2x
LAURUSLABS Laurus Labs	₹1.84k	3.0% +₹29.0b	119.4%	PE90.6x
ALIVUS Alivus Life Sciences	₹1.33k	18.9% +₹25.9b	40.0%	PE27.1x
500124 Dr. Reddy's Laboratories	₹1.17k	2.7% +₹25.7b	-1.9%	PE29.5x
530549 Shilpa Medicare	₹721.35	19.3% +₹22.8b	75.5%	PE58x

Fresenius Kabi Announces FDA Approval of Rituximab Biosimilar Developed by Dr. Reddy's Laboratories for U.S. Market

Fresenius Kabi, an operating company of Fresenius, announced that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories, a biosimilar to Rituxan (rituximab). Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize the biosimilar in the United States. The product was developed, manufactured, and submitted for approval by Dr. Reddy's Laboratories. Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications. Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on B lymphocytes. It is widely used in the treatment of adults with several B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as certain autoimmune conditions. The FDA approval is supported by a totality of the evidence approach, including analytical, non-clinical, and clinical data demonstrating that the product is highly similar to and has no clinically meaningful differences from the reference product, Rituxan, consistent with U.S. FDA requirements for biosimilar approval. Rituximab is approved for the treatment of adults with several hematologic malignancies and autoimmune diseases in the United States, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). Rituximab products have a Boxed Warning for fatal infusion-related reactions, severe mucocutaneous reactions, HBV reactivation, and progressive multifocal leukoencephalopathy (PML). Serious infections and other significant adverse reactions may also occur. The rituximab biosimilar was developed and manufactured by Dr. Reddy's Laboratories. Fresenius Kabi holds exclusive commercialization rights in the United States. The biosimilar development program was designed to demonstrate high similarity to the reference product through comprehensive analytical, non-clinical, pharmacokinetic, and clinical studies, in line with FDA requirements for biosimilar approval.

Indian (NIFTY) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Fresenius Kabi Announces FDA Approval of Rituximab Biosimilar Developed by Dr. Reddy's Laboratories for U.S. Market

Piramal Pharma Limited Expands Peptide API Facility with Advanced Spray Drying Suite

Price target increased by 7.4% to ₹1,482

Full year 2026 earnings released: EPS: ₹25.15 (vs ₹52.98 in FY 2025)

Investor sentiment improves as stock rises 19%

Results: Sun Pharmaceutical Industries Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2027 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased by 7.2% to ₹1,335

Price target increased by 8.3% to ₹5,322

Here's What Analysts Are Forecasting For Eris Lifesciences Limited (NSE:ERIS) After Its First-Quarter Results

New minor risk - Earnings quality

MANKIND: Subsidiary Moves And Margin Outlook Will Support Future Re Rating

High number of new directors

Lupin Limited Launches Generic Sugammadex Injection In The U.S. After Receiving U.S. FDA Approval

Cipla Limited Receives U.S. Fda Approval for Generic Advair Diskus

Full year 2026 earnings released: EPS: ₹13.11 (vs ₹3.00 loss in FY 2025)